Filing Flows

Filing Flows › Companies › Vera Therapeutics › Cash flow

Vera Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$99.2M in Q3 2026 · −$376M over twelve months

Operating cash flow−$99.2M
Free cash flow−$99.2M

Analysis

In Q3 2026, Vera Therapeutics generated −$99.2M of operating cash flow. That is $37.1M less than in Q3 2025 (−$62.0M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$376M; the largest uses were operating cash flow ($376M), capital spending ($125K); besides operations, cash came from other financing ($282M), other investing ($77.7M); the cash balance fell by $2.5M.

Operating cash flow was −$99.2M against net income of −$93.7M. The largest differences: stock-based pay +$15.7M, prepaid and other assets −$9.8M, payables +$5.6M.

Free cash flow

Vera Therapeutics: free cash flow by quarterVera Therapeutics: free cash flow by quarter−$39.8MQ4 2024−$54.6MQ1 2025−$55.0MQ2 2025−$62.0MQ3 2025−$70.1MQ4 2025−$107MQ1 2026−$100MQ2 2026−$99.2MQ3 2026
Operating cash flow less capital spending.
Vera Therapeutics: operating cash flow against capital spendingVera Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$39.2M$645KQ4 2024−$54.4M$187KQ1 2025−$54.8M$208KQ2 2025−$61.9M$133KQ3 2025−$70.0M$102KQ4 2025−$106M$23KQ1 2026−$100M$0Q2 2026−$99.2M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$99.2M, Capital spending $0.

Capital allocation, year by year

Vera Therapeutics: where the cash came from (up) and went (down), by fiscal yearVera Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow −$23.7MFY2021: Shares issued $550KFY2021: Asset sales $796K$1.3MFY2021FY2022: Operating cash flow −$67.6MFY2022: Shares issued $4.1MFY2022: Capital spending −$62K$4.1MFY2022FY2023: Operating cash flow −$92.2MFY2023: Shares issued $1.1MFY2023: Capital spending −$63K$1.1MFY2023FY2024: Operating cash flow −$135MFY2024: Shares issued $13.4MFY2024: Capital spending −$972KFY2024: Buybacks −$13K$13.4MFY2024FY2025: Operating cash flow −$241MFY2025: Shares issued $7.0MFY2025: Capital spending −$630K$7.0MFY2025
Over these 5 years operating cash flow totalled −$559M; the largest uses were operating cash flow ($559M) and capital spending ($1.7M). Cash-flow statements as filed.

Where the cash came from and went

Vera Therapeutics: sources (+) and uses (−) of cash, Q3 2026Vera Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other investing$102MOperating cash flow−$99.2MCash drawn (+) / kept (−)−$6.4MShares issued$3.7M
Vera Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Vera Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$376MOther financing$282MOther investing$77.7MShares issued$13.8MCash drawn (+) / kept (−)$2.5MCapital spending−$125K

From profit to cash

Vera Therapeutics: net income to operating cash flow, Q3 2026Vera Therapeutics: net income to operating cash flow, Q3 2026Net income−$93.7MDepreciation & amortization$823KStock-based pay$15.7MPayables$5.6MAccrued liabilities$1.5MPrepaid and other assets−$9.8MOperating cash flow−$99.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$99.2M—$3.7M−$6.4M−$99.2M
Q2 2026−$100M—$1.9M$65.5M−$100M
Q1 2026−$106M−$23K$3.9M$240M−$107M
Q4 2025−$70.0M−$102K$4.2M−$297M−$70.1M
Q3 2025−$61.9M−$133K$797K−$8.7M−$62.0M
Q2 2025−$54.8M−$208K$464K$6.0M−$55.0M
Q1 2025−$54.4M−$187K$1.5M$37.6M−$54.6M
Q4 2024−$39.2M−$645K$2.3M−$65.4M−$39.8M

Vera Therapeutics: income statement and cash flow

Vera Therapeutics, Q3 2026: revenue $10.3M, operating margin -931.2%. The chart follows the revenue to costs, profit and cash.

Vera Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.